Literature DB >> 11552989

Mutation screening of the c-MYB negative regulatory domain in acute and chronic myeloid leukaemia.

J K Lutwyche1, R A Keough, T P Hughes, T J Gonda.   

Abstract

Over-expression of the c-myb gene and expression of activated forms of myb are known to transform haemopoietic cells, particularly cells of the myeloid lineage. Truncations or mutations that disrupt the negative regulatory domain (NRD) of the Myb protein confer an increased ability to transform cells. Although it has proved difficult to link mutations in c-MYB to human leukaemia, no studies investigating the presence of mutations within the c-MYB NRD have been reported. Therefore, we have performed mutational analysis of this region, using polymerase chain reaction-single-stranded conformation polymorphism and sequence analysis, in 26 patients with acute or chronic myeloid leukaemia. No mutations were detected, indicating that mutation of this region of the Myb protein is not common in the pathogenesis or progression of these diseases.

Entities:  

Mesh:

Year:  2001        PMID: 11552989     DOI: 10.1046/j.1365-2141.2001.02966.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

1.  Requirement of c-Myb for p210(BCR/ABL)-dependent transformation of hematopoietic progenitors and leukemogenesis.

Authors:  Maria Rosa Lidonnici; Francesca Corradini; Todd Waldron; Timothy P Bender; Bruno Calabretta
Journal:  Blood       Date:  2008-01-28       Impact factor: 22.113

2.  miR-150 functions as a tumour suppressor in human colorectal cancer by targeting c-Myb.

Authors:  Junlan Feng; Yongzhi Yang; Peng Zhang; Feng Wang; Yanlei Ma; Huanlong Qin; Yu Wang
Journal:  J Cell Mol Med       Date:  2014-09-18       Impact factor: 5.295

3.  Leprosy drug clofazimine activates peroxisome proliferator-activated receptor-γ and synergizes with imatinib to inhibit chronic myeloid leukemia cells.

Authors:  Harish Kumar; Sourav Chattopadhyay; Nabanita Das; Sonal Shree; Dinesh Patel; Jogeswar Mohapatra; Anagha Gurjar; Sapana Kushwaha; Abhishek Kumar Singh; Shikha Dubey; Kiran Lata; Rajesh Kushwaha; Riyazuddin Mohammed; Krishnarup Ghosh Dastidar; Namrata Yadav; Achchhe Lal Vishwakarma; Jiaur Rahaman Gayen; Sanghamitra Bandyopadhyay; Abhijit Chatterjee; Mukul Rameshchandra Jain; Anil Kumar Tripathi; Arun Kumar Trivedi; Naibedya Chattopadhyay; Ravishankar Ramachandran; Sabyasachi Sanyal
Journal:  Haematologica       Date:  2019-08-01       Impact factor: 9.941

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.